Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe most common side effects of Mounjaro are gastrointestinal: nausea, diarrhoea, constipation, vomiting, indigestion and stomach discomfort. These affect a significant proportion of people, particularly in the first few weeks after starting or after a dose increase, and they usually settle as the body adjusts. Mounjaro (tirzepatide) is a prescription-only medicine; a prescriber assesses your full medical picture before it is issued, and side effects are part of that clinical conversation. This page covers what the evidence shows, what tends to pass on its own, and — critically — which symptoms need prompt medical attention.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most persistent misconception about Mounjaro side effects is that experiencing nausea or loose stools in the first couple of weeks signals a problem with the medicine, or that you should stop taking it straight away. In the vast majority of cases, the opposite is true. These reactions reflect the medicine working as intended: tirzepatide slows gastric emptying and changes gut-hormone signalling, and those same mechanisms are what drive appetite reduction and weight loss. The body needs a short period to recalibrate.
The licensed dosing structure builds this in deliberately. Treatment begins at 2.5 mg, a dose whose primary job is letting your system adapt, not yet delivering the full therapeutic effect. As the NHS tirzepatide medicines page explains, GI symptoms are expected at the start and tend to improve with time. Most people find the nausea most noticeable in the day or two after an injection, then fading over the following days. By the time a dose increase is reached (typically at four-week intervals under a prescriber's guidance) many people report tolerating it well.
That said, the myth runs in both directions. Some people start Mounjaro expecting severe nausea and are pleasantly surprised; others are caught off guard. Knowing what is normal, what typically passes, and what falls outside that range is the useful preparation. The sections below cover exactly that, drawing on the medicine's SmPC and clinical trial data.
Across the SURMOUNT clinical programme, the most frequently reported side effects were nausea, diarrhoea, vomiting, constipation, abdominal pain, dyspepsia (indigestion) and burping. Fatigue, headache, dizziness and injection-site reactions also appeared, though less often. These findings are consistent with what the Mounjaro SmPC on the eMC lists as common adverse effects.
In practical terms, nausea tends to arrive in the first day or so after an injection and ease off by day three or four. Constipation, when it occurs, can be more persistent, staying well hydrated and keeping fibre intake up makes a noticeable difference for many people. Diarrhoea is less common than constipation overall, though it can occur, particularly at higher doses. Injection-site reactions (mild redness or itching at the abdomen, thigh or upper arm) are generally transient and improve with rotating the site each week.
Hair thinning is another concern that comes up regularly. It is not listed as a common adverse effect of tirzepatide itself; rather, it is associated with rapid weight loss generally (a condition called telogen effluvium), and it is usually temporary. There is a fuller explanation of hair loss on Mounjaro if that is a specific concern for you.
One thing our prescribers hear most weeks: people worried that a single bad night of nausea means they cannot continue. Usually that is not the case, pacing meals, eating smaller portions, and avoiding fatty or very rich food in the hours around an injection all help. Your prescriber and the Patient Information Leaflet are the right places to get personalised support on managing these effects.
Not every side effect is something to ride out. Some require prompt medical attention, and it is important to know which.
The MHRA's January 2026 Drug Safety Update for GLP-1 medicines specifically highlighted acute pancreatitis as an infrequent but potentially serious side effect. The warning sign to act on is severe, persistent stomach pain (the kind that does not settle and may radiate through to the back) with or without vomiting. If that happens, stop taking your next dose and seek urgent medical attention. Do not wait to see whether it passes on its own.
Other symptoms that warrant contacting a doctor promptly include: signs of a serious allergic reaction (swelling of the face, lips, tongue or throat; difficulty breathing; rash); symptoms suggesting gallbladder problems (sudden pain in the upper right abdomen, especially after eating); and signs of significant dehydration following severe vomiting or diarrhoea, such as very little or no urination, confusion or extreme dizziness. If you are also being treated for diabetes, low blood sugar is an additional consideration to discuss with your prescriber.
Side effects can also be reported directly to the MHRA via the Yellow Card scheme, this applies both to reactions you experience yourself and to any medicine you suspect may be counterfeit or substandard. It is a straightforward online process and genuinely useful for post-market surveillance.
For a broader look at Mounjaro side effects across all categories, including less common reactions, the dedicated overview page covers more ground. The BNF listing for tirzepatide side effects is the professional-level reference if you want the full clinical detail.
Because Mounjaro is a prescription-only medicine, the clinical assessment before it is issued is not a formality. At nume, a GPhC-registered Independent Prescriber reads your consultation answers personally, the same day, not via automated software. They look at your medical history, current medicines and any contraindications before approving treatment, and they factor the likely side-effect profile into that decision.
Our prescribers discuss suitability and anticipated side effects as part of every consultation. If you are already taking Mounjaro elsewhere and considering switching, or if you want to understand how the tirzepatide side-effect profile compares across the available evidence, that is all part of what the free consultation covers. You can also review how Mounjaro works and what the treatment involves before you start.
After treatment is issued, our aftercare team is available seven days a week. That matters in practice: if nausea hits on a Saturday afternoon before the school run, you do not need to wait until Monday to ask whether it is expected. If you have questions about cost alongside clinical questions, Mounjaro pricing at nume is set out clearly. And if you are ready to talk through suitability, start your free consultation and speak to our prescribers directly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.